Bioventus (BVS)

Search documents
Bioventus (BVS) - 2022 Q3 - Earnings Call Transcript
2022-11-11 17:14
Bioventus Inc. (NASDAQ:BVS) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Drew Ranieri - Morgan Stanley Philip Coover - Goldman Sachs Rohin Patel - JPMorgan Operator Good day, and welcome to Bioventus Inc. Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only ...
Bioventus (BVS) - 2022 Q2 - Earnings Call Transcript
2022-08-11 18:58
Bioventus Inc. (NASDAQ:BVS) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Robbie Marcus - JPMorgan Drew Ranieri - Morgan Stanley Phil Coover - Goldman Sachs Operator Good morning, and welcome to the Bioventus Incorporated Second Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. ...
Bioventus (BVS) - 2022 Q2 - Earnings Call Presentation
2022-08-11 16:54
August 11, 2022 Q1 2021 Results Innovations For Active Healing Second Quarter 2022 Financial Results Agenda and Speakers Ken Reali Chief Executive Officer Q2 2022 Review Progress on 2022 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q2 2022 Results CartiHeal Financing 2022 Guidance Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of ...
Bioventus (BVS) - 2022 Q1 - Earnings Call Transcript
2022-05-10 18:22
Bioventus Inc. (NASDAQ:BVS) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Dave Crawford - Vice President of Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Office Conference Call Participants Alex Nowak - Craig Hallum Operator Good day and thank you for standing by. Welcome to Bioventus First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that todayÂ's conference is being recor ...
Bioventus (BVS) - 2022 Q1 - Earnings Call Presentation
2022-05-10 12:56
May 10, 2022 Q1 2021 Results Innovations For Active Healing First Quarter 2022 Financial Results Agenda and Speakers Ken Reali Chief Executive Officer Q1 2022 Review Progress on 2022 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q1 2022 Results 2022 Guidance Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Se ...
Bioventus (BVS) - 2021 Q4 - Earnings Call Presentation
2022-03-11 05:41
Q1 2021 Results Innovations For Active Healing Fourth Quarter 2021 Financial Results March 10, 2022 Agenda and Speakers Ken Reali Chief Executive Officer Q4 2021 Review 2022 Priorities Dave Crawford Vice President Investor Relations and Treasurer Q4 2021 Results 2022 Guidance Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of ...
Bioventus (BVS) - 2021 Q4 - Earnings Call Transcript
2022-03-10 16:42
Bioventus Inc. (NASDAQ:BVS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Ken Reali – Chief Executive Officer Dave Crawford – Vice President of Investor Relations Conference Call Participants Kyle Rose – Canaccord Genuity Drew Ranieri – Morgan Stanley Robbie Marcus – JP Morgan Phil Coover – Goldman Sachs Operator Thank you for standing by and welcome to the Bioventus Incorporated, Fourth Quarter 2021 earnings conference call. At this time, all participants are in a listen- ...
Bioventus (BVS) - 2021 Q4 - Annual Report
2022-03-10 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-K ________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37844 BIOVENTUS INC. (Exact Name of Registrant as Spec ...
Bioventus (BVS) - 2021 Q3 - Earnings Call Transcript
2021-11-14 16:45
Financial Data and Key Metrics Changes - Revenue increased by 27% for the quarter to $109 million, with 14% organic growth and a 13% contribution from Bioness [7][25] - Adjusted EBITDA totaled $21 million, compared to $23 million in the prior year, primarily due to higher operating costs [29] - Adjusted diluted earnings per share were $0.25, up from $0.24 a year ago [29] Business Line Data and Key Metrics Changes - Pain treatments grew by 24%, with 21 percentage points from organic growth and 3 percentage points from PNS products [25] - Bone graft substitutes saw 4% growth, impacted by COVID-related hospitalizations, but year-to-date growth was 35% compared to 2020 [26] - Restorative therapies delivered 52% growth, with 6 percentage points from Exogen and 46 percentage points from Bioness Advanced Rehabilitation [27] Market Data and Key Metrics Changes - International segment growth was 39%, with organic growth of 11% for the quarter [14] - DUROLANE revenue has more than doubled in the U.S. and nearly doubled globally compared to two years ago [25] - The company expects to trend closer to a normal environment by the end of the fourth quarter [26] Company Strategy and Development Direction - The company is focused on integrating Bioness and Misonix to enhance growth and market share [18][19] - The acquisition of Misonix is expected to create a high-growth medical device company with a $15 billion total addressable market [18] - The company aims to maintain double-digit organic growth while successfully integrating recent acquisitions [58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate challenges posed by the pandemic and maintain growth [6][42] - The company anticipates gradual improvement in operating conditions and expects to achieve stronger performance in the fourth quarter [26] - Management highlighted the importance of their diversified portfolio and strong market access strategies in driving growth [42] Other Important Information - The company has placed a $50 million deposit for the potential acquisition of CartiHeal, which targets a $1.3 billion addressable market [20][21] - The integration of Bioness is progressing as planned, with breakeven profitability reached by the end of Q3 [15][19] - The company has a solid balance sheet with $81 million in cash and $177 million in debt outstanding at the end of the quarter [30] Q&A Session Summary Question: Trends in pain treatment and joint preservation - Management noted that the pandemic has created choppiness in elective procedures but access to physicians remained stable [36] Question: Cross-selling synergies from Bioness acquisition - Management expects increased sales synergies from the integration of Bioness, particularly in 2022 [38][39] Question: Confidence in normalization of business - Management attributed resilience to their dedicated team and diversified product offerings, which have allowed them to perform better than peers [42][44] Question: Misonix portfolio performance - Management indicated that Misonix has continued to grow despite headwinds, with a balanced portfolio across elective and wound treatment [46] Question: Long-term growth and margin profile - Management emphasized that both Bioness and Misonix are expected to drive consistent double-digit growth and maintain historical margin profiles [50] Question: International growth initiatives - Management highlighted plans to leverage their direct sales organizations to enhance international growth, which is currently below peers [52][53] Question: Feedback on DUROLANE's clinical data - Management reported positive feedback from clinicians regarding DUROLANE's high molecular weight and its potential to capture more market share [56]
Bioventus (BVS) Presents At Canaccord Genuity 41st Annual Growth Conference - Slideshow
2021-08-30 19:36
Bioventus Inc. Investor Presentations – August 2021 @bioventus® Disclaimer Forward-Looking Information This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning our business ...